Efficacy and safety of etanercept biosimilar rhTNFR-Fc in Chinese patients with juvenile idiopathic arthritis: An open-label multicenter observational study

• Main Authors: Xuefeng Xu (Author), Xiaohui Liu (Author), Wenjie Zheng (Author), Jihong Xiao (Author), Xiaozhong Li (Author), Ling Wu (Author), Lixia Zou (Author), Qian Ouyang (Author), Yaoyao Shangguan (Author), Kezhao Lin (Author), Xiaomei Dai (Author), Yuanling Chen (Author), Yiping Xu (Author), Jianqiang Wu (Author), Meiping Lu (Author)
• Format: Book
• Published: Frontiers Media S.A., 2022-10-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

BackgroundEtanercept biosimilar recombinant human TNF-α receptor II: IgG Fc fusion protein (rhTNFR-Fc) has showed its efficacy and safety in Chinese patients with rheumatoid arthritis. However, data on rhTNFR-Fc's application in juvenile idiopathic arthritis (JIA) is limited.MethodsA prospectiv...